Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
“The paper under evaluation describes the topical use of resiquimod , a TLR7/8 agonist, to enhance cross-priming to subcutaneously administered ovalbumin.”